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Abstract 
Purpose: The aim of this study was to determine whether gastrointestinal (GI) 
distress affects the ergogenicity of sodium bicarbonate and whether the degree of 
alkalaemia or other metabolic responses are different between individuals who 
improve exercise capacity and those who do not. Methods: Twenty-one males 
completed two cycling capacity tests at 110% of maximum power output. Participants 
were supplemented with 0.3 g∙kg-1BM of either placebo (maltodextrin) or sodium 
bicarbonate (SB). Blood pH, bicarbonate, base excess and lactate were determined at 
baseline, pre-exercise, immediately post-exercise and 5 minutes post-exercise. 
Results: SB supplementation did not significantly increase total work done (TWD) (P 
= 0.16, 46.8 ± 9.1 vs. 45.6 ± 8.4 kJ, d = 0.14), although magnitude based inferences 
suggested a 63% likelihood of a positive effect. When data were analysed without 
four participants who experienced GI discomfort, TWD (P = 0.01) was significantly 
improved with SB. Immediately post-exercise blood lactate was higher in SB for the 
individuals who improved but not for those who didn’t. There were also differences in 
the pre to post-exercise change in blood pH, bicarbonate and base excess between 
individuals who improved and individuals who did not. Conclusions: SB improved 
high intensity cycling capacity, but only with the exclusion of participants 
experiencing GI discomfort. Differences in blood responses suggest that sodium 
bicarbonate may not be beneficial to all individuals. Magnitude based inferences 
suggested that the exercise effects are unlikely to be negative; therefore individuals 
should determine whether they respond well to sodium bicarbonate supplementation 
prior to competition.  
Key words: Extracellular buffering, high-intensity exercise, gastrointestinal distress, 
blood responses, inter-individual variability 
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Introduction 
The effects of sodium bicarbonate supplementation on exercise performance and 
capacity have been well researched (for review see 1), and a recent meta-analysis 
showed that 0.3 g·kg-1Body Mass (BM) sodium bicarbonate supplementation prior to 
a 60 s sprint improved performance by 1.7 ± 2.0% 2. Despite this, the reported effects 
are equivocal, with several studies reporting no effect on exercise performance and 
capacity 3, 4, 5, 6, 7. Inconsistencies in the performance outcomes of sodium bicarbonate 
supplementation studies can be partly attributed to differing dosing regimens 4, 
gastrointestinal (GI) discomfort experienced by some participants 8, exercise models 
insufficient to be limited by hydrogen cation (H+) accumulation 5 and individual 
variation in the response to supplementation 9.  
 
To determine the true effect of sodium bicarbonate supplementation on exercise, an 
appropriate exercise test to investigate the effects of increased buffering capacity 
should be of a sufficient intensity to result in a large accumulation of H+, and 
therefore be limited by increasing muscle acidosis. Recently, Higgins et al. 10 showed 
that sodium bicarbonate improved exercise capacity at 100% peak mean minute 
power, but not 110 or 120%. However, using a high-intensity cycling capacity test 
performed to exhaustion at 110% of previously determined Powermax (CCT110%), 
previous studies have shown the CCT110% to be positively influenced by a dietary 
intervention (β-alanine supplementation to increase muscle carnosine levels) known 
to increase intracellular pH buffering 11, 12. This test was designed 11 to last between 
120 and 240 s, and has been shown to be reliable with a coefficient of variation (CV) 
of 4.94% for total work done 13, which suggest that the CCT110% is an appropriate 
model for examining the effects of dietary interventions designed to manipulate 
intramuscular changes in pH during exercise. 
 
A potential moderator of the ergogenic effect of sodium bicarbonate supplementation 
on exercise capacity and performance is the gastrointestinal (GI) discomfort 
experienced by some participants. Price and Simons 9 suggested that the need to 
individualise supplementation with sodium bicarbonate was related to the individuals’ 
susceptibility to GI discomfort, although GI discomfort was not correlated with 
performance decrements in their study. Van Montfoort et al. 14 measured the intensity 
of sickness and stomach ache prior to, and following high-intensity exercise, but 
reported little or no GI symptoms following supplementation with 0.3 g·kg-1BM 
sodium bicarbonate. McNaughton 8 reported increased GI disturbance in all 
participants consuming doses above 0.3 g·kg-1BM which may also explain the lack of 
a further increase in cycling capacity shown in these participants. The data of 
McNaughton 8 suggest 0.3 g·kg-1BM to be the optimal dose to improve exercise 
performance or capacity with limited GI discomfort. 
 
Matson and Tran 15 reported a relatively weak relationship (r = 0.42) between the 
dose of sodium bicarbonate and the resulting degree of blood alkalosis following 
supplementation using a meta-analysis of the literature. It was hypothesised that this 
was due to the large variability in individual pH and bicarbonate responses to 
supplementation, which suggests that the purported mechanism underlying a potential 
ergogenic effect of sodium bicarbonate supplementation might not have been present 
in all individuals. Most previous research has focused on the mean effect of sodium 
bicarbonate supplementation within the trial group, thereby disregarding individual 
variation, and this may have served to mask its true effect. Thus, inconsistencies in 
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previous findings could be explained by variability in individual responses to sodium 
bicarbonate supplementation, which, when analysed as group means with small 
sample numbers, do not represent its true effect. Therefore, it would be of interest to 
separate those who improved with sodium bicarbonate from those who did not, and 
investigate their blood responses to supplementation and exercise to determine any 
differences. 
 
The present study was tightly controlled in an attempt to limit several contributing 
factors that may have contributed to equivocal results of sodium bicarbonate on 
exercise performance and capacity in the literature. This was achieved by employing 
the ‘optimal’ dose 8 using a split-dose strategy to minimise GI discomfort; employing 
a reliable 13 exercise test previously suggested to be limited by increasing muscle 
acidosis 11, 12; and separating participants into those who improved their cycling 
capacity above the CV of the test and those who did not to determine any differences 
in blood responses. The primary aim of this study was to investigate the effect of 
sodium bicarbonate on cycling capacity and determine whether GI distress affects the 
efficacy. A secondary aim of this investigation was to determine whether the degree 
of blood alkalosis or other metabolic responses are different between individuals who 
improved exercise capacity and those who did not.   
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Materials and Methods 
Participants 
Twenty-one recreationally active males (mean ± SD; age 25 ± 5 y, body mass 80.7 ± 
10.6 kg, height 1.79 ± 0.06 m, maximum cycling output [Wmax] 316 ± 45 W) 
volunteered and gave their written informed consent to participate in this study. 
Participants were required not to have taken any supplement in the three months prior 
to taking part. The study was first approved by the institution’s Ethics Review 
Committee. 
 
Experimental Design 
Participants were required to attend the laboratory on four separate occasions over a 
fourteen day period. All trials were performed at the same time of day to ensure 
results were not affected by circadian variation 16. There were two preliminary trials, 
which comprised of an incremental cycle to exhaustion to determine Wmax, followed 
by a habituation trial with the cycle capacity test to exhaustion at 110% of Wmax 
(CCT110%). Participants then completed two repeated measures, counterbalanced and 
double-blind trials following the ingestion of 0.3 g·kg-1BM of either sodium 
bicarbonate (SB) or maltodextrin (P). All supplements were tested by HFL Sport 
Science prior to use to ensure no contamination with steroids or stimulants according 
to ISO 17025 accredited tests.  
 
Design 
Preliminary Testing 
Each participant performed a graded cycle capacity test to exhaustion on a cycle 
ergometer (Lode Excalibur, Germany) to determine individual Wmax. Exercise 
commenced at a self-selected power between 100 and 150 W, and was increased by 6 
W every 15 s (ramp rate of 24 W·min-1) until participants reached volitional 
exhaustion. The maximum power output averaged over the final two stages was 
defined as an individual’s Wmax. 
 
Every participant performed a habituation CCT110% to minimise any learning effect 
during the main trials. A 5 min cycling warm up was performed at 100 W followed by 
a 2 min period of stretching. Since participants were not highly trained cyclists, each 
participant’s CCT110% was incremented over the first 30 s which corresponded to 80% 
Wmax during the first 15 s, 95% Wmax over the second 15 s followed by 110% Wmax 
until volitional exhaustion 13. Individual set up of the cycle ergometer (saddle and 
handlebar height and length) was determined prior to the initial Wmax trial and was 
maintained for all subsequent CCT110% trials. Participants pedalled at a self-selected 
pedal cadence (range 80-100 rev·min-1 across participants) and were required to 
maintain this cadence throughout the entire test. Verbal encouragement was given 
throughout. Volitional exhaustion was deemed to have occurred when participants 
dropped 20 rev·min-1 below their self-selected pedal cadence, at which point they 
were instructed to stop pedalling.  
 
Main Trials 
Twenty-four hours prior to the main trials, participants were required to refrain from 
alcohol, caffeine and any strenuous exercise. Food intake was monitored during the 
twenty-four hours prior to the first main trial using a food diary and replicated prior to 
the second main trial. Following an overnight fast, participants arrived at the 
laboratory 4 h before the CCT110%. Baseline finger-prick blood samples were taken 
6 
 
before consuming a standardised breakfast of 3 slices of toast and jam at 09:00. 
Participants ingested 0.2 g·kg-1BM of sodium bicarbonate (SIS, UK) or matching 
placebo (maltodextrin; SIS, UK) alongside the breakfast. A final 0.1 g·kg-1BM was 
ingested 2 h after the standardised breakfast (11:00), 2 h prior to commencement of 
the CCT110% (13:00). All supplements were administered in gelatine capsules. 
Participants were instructed to report any gastrointestinal or other symptoms 
experienced during the four hours prior to exercise. They were requested to note down 
the time, type (stomach cramps, bloating, headaches) and the severity (mild, moderate 
or severe) of symptoms.  
 
Participants performed the CCT110% as described above for the habituation trial, with 
TWD being recorded as the outcome measure. Arterialised finger-prick blood samples 
were taken at rest, immediately pre-, immediately post- and 5-min post-exercise. 
Blood samples were analysed for lactate (Lactate Pro, Arkray, Japan), pH, 
haemoglobin (Hb) and blood gases (Radiometer ABL 400, UK). Blood bicarbonate 
was calculated from PCO2 and pH values according to the Henderson-Hasselbalch 
equation and base excess was calculated according to ((1 – 0.014[Hb]) x ([HCO3-] – 
24 + (1.43[Hb] + 7.7) (pH – 7.4))). 
 
Statistical Analysis 
All data were analysed using Statistica 9 (Statsoft, USA) and are presented as mean ± 
1SD. Data were analysed for the trial effect of sodium bicarbonate supplementation in 
all participants (N = 21). The data were then analysed following the exclusion of 
participants experiencing GI discomfort (N = 17). In addition, the complete data set 
was split into two groups, categorising participants as those who improved (N = 9), in 
whom exercise capacity was improved above the CV of the CCT110% (4.94%; 
Saunders et al. 13), and those who did not (N = 12), in whom exercise capacity was 
not improved above the CV of the test. Paired samples t-tests were used to determine 
any differences in performance measures between supplementation trials. A two-way 
ANOVA (trial x time) with repeated measures was used to determine any difference 
in blood pH, lactate, bicarbonate and base excess levels. Mauchly’s test of Sphericity 
was used to check the data for sphericity, and where it was violated, a Greenhouse-
Geisser correction was applied. A post-hoc Bonferroni correction factor was used to 
test any differences indicated by the ANOVA. Effect sizes were calculated using 
Cohen’s d 17. Pearson’s correlations were used to determine any association in 
exercise and blood variables. In addition, magnitude based inferences 18 were used to 
determine the practical significance of sodium bicarbonate on the CCT110% using a 
spread sheet to establish the likelihood of a meaningful effect on exercise capacity. 
The smallest worthwhile improvement in TWD was 1.27 kJ which was equivalent to 
half the unbiased typical error associated with the measurement. Statistical 
significance was accepted at the P ≤ 0.05 level.  
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Results 
All Participants (N = 21) 
Total work done was not significantly different between conditions (P = 0.16, d = 
0.14) (Table 1). Magnitude based inferences showed that the effect of SB on TWD 
was possibly beneficial (63% positive, 36% trivial, 1% negative).  
 
There was no difference in baseline pH, bicarbonate, base excess or lactate between 
trials (Table 2). Supplementation with SB, but not P, significantly increased pre-
exercise pH, bicarbonate and base excess levels from baseline (P ≤ 0.001). Blood pH, 
bicarbonate and base excess measured immediately post-exercise and 5 minutes post-
exercise (Table 2) were significantly decreased from baseline in both P and SB (P ≤ 
0.001); with values being significantly higher in SB (P ≤ 0.001). Blood lactate (Table 
2) was significantly increased from baseline following exercise in both trials (P ≤ 
0.001), with significantly higher post-exercise concentrations shown following SB (P 
≤ 0.001). 
 
Total work done was not correlated with pre-exercise pH (r = -0.05), bicarbonate (r = 
0.03) or base excess (r = 0.01), nor with their changes from baseline to pre-exercise. 
However, TWD was significantly correlated with the changes in pH (r = -0.43, P = 
0.004), bicarbonate (r = -0.41, P = 0.008) and base excess (r = -0.45, P = 0.003) from 
pre- to post-exercise, although there was no significant correlation with the change in 
lactate.  
 
Participants Not Experiencing GI Discomfort (N = 17) 
Any participant reporting symptoms of moderate to severe discomfort following SB 
ingestion was considered an individual with GI discomfort; four participants were 
categorised as such, with the most frequently reported symptoms being moderate to 
severe stomach cramps and diarrhoea. When data were analysed without those 
participants experiencing GI discomfort, TWD was significantly increased (P = 0.01, 
d = 0.25) in SB compared with P (Table 1). Magnitude based inferences showed that 
the effect of SB was probably beneficial (78% positive, 22% trivial, 0% negative).  
 
Blood responses to supplementation and exercise were similar to the whole group 
blood responses (Table 2). In addition, the removal of participants who experienced 
GI discomfort from the analyses did not influence the significance of any of the 
correlations that were performed on the full data-set. 
  
Improved (N = 9) and Non-Improved (N = 12) 
There was a degree of individual variability in exercise capacity between P and SB for 
all participants, with the difference in TWD between trials ranging from -5.1 to +8.1 
kJ (Figure 1). Twelve participants increased TWD following SB supplementation. 
Nine participants improved above the 4.94% test retest variability for TWD during the 
CCT110% 
13. The remaining twelve individuals who did not improve (N = 9) or who 
did not improve above the CV of the CCT110% (N = 3) were allocated to the non-
improved group.  
 
Exercise capacity was significantly different between trials for the improved group (P 
≤ 0.001) but not for non-improved (P = 0.12; Table 1). Magnitude based inferences 
showed that the effect of SB for the improved group was almost certainly beneficial 
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(100% positive, 0% trivial, 0% negative) and possibly trivial for the non-improved 
group (11% positive, 72% trivial, 16% negative). 
 
Blood pH, bicarbonate and base excess levels were significantly increased in both 
groups, from baseline to pre-exercise in SB only (Table 3). In the group who 
improved, the reduction in pH, bicarbonate and base excess from pre- to post-exercise 
was greater in SB than in P (P ≤ 0.01). In the non-improved group, there was no 
difference in the reduction in pH, bicarbonate or base excess from pre- to post-
exercise between trials (all P > 0.05). Immediately-post exercise blood lactate 
concentrations were significantly higher in SB for the improved group (P = 0.003) but 
not for the non-improved group (P = 0.35). 
 
Total work done was not correlated with any pre-exercise blood marker for the 
improved and non-improved groups, or with their changes from baseline to pre-
exercise. Total work done was not significantly correlated with any blood changes 
from pre- to post-exercise in the individuals who improved, but was correlated to the 
change in pH, bicarbonate and base excess in the group who were not improved (all P 
≤ 0.05). 
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Discussion 
The current study showed that TWD during the CCT110% was unaffected by sodium 
bicarbonate supplementation in all participants, despite resulting in alkalaemia prior 
to exercise, although magnitude based inferences suggest a 63% likelihood that the 
difference between conditions was meaningful. The lack of an effect may have been 
due to GI distress experienced by several individuals, since a positive effect was 
shown following the removal of those experiencing GI discomfort. This could not 
explain the lack of an effect in all participants; there were some differences in blood 
responses to supplementation and exercise which may have contributed to the 
variability in results. 
 
The results of the present study are in contrast to several studies using β-alanine 
supplementation 11, 12 that have shown significant increases in TWD using the same 
exercise test. However, any contrast in findings between β-alanine and sodium 
bicarbonate supplementation may be due to carnosine’s more direct influence upon 
intramuscular pH. In addition, Sale et al. 12 showed a further 4.3% increase in TWD 
when participants supplemented with β-alanine co-ingested sodium bicarbonate, 
although this was non-significant, a 70% likelihood of a meaningful difference was 
shown. Similarly, the authors showed some variability in the exercise response to 
sodium bicarbonate which may have contributed to the lack of an effect. 
 
Price and Simons 9 reported no significant effect of sodium bicarbonate 
supplementation on high intensity running performance lasting around 75 s. The 
authors suggested that GI discomfort or individual differences in the blood responses 
to supplementation might explain the negative findings. Despite the split-dose 
strategy used in the present study, several participants reported symptoms of 
discomfort. As such, we analysed our data following the exclusion of the four 
participants who reported significant GI discomfort following sodium bicarbonate 
supplementation. None of the four participants reporting GI discomfort showed an 
increased exercise capacity following sodium bicarbonate supplementation, meaning 
that a significant improvement in high intensity exercise capacity was shown when 
group data were analysed following the exclusion of these participants. GI discomfort 
only partially explained the lack of an improvement in exercise capacity; however, 
twelve participants did not show any improvements in exercise capacity with sodium 
bicarbonate supplementation. This suggests that some other physiological differences 
between participants might also help to explain the individual capacity response. 
 
Increases in blood bicarbonate concentration and subsequently blood alkalosis were 
shown in all participants prior to exercise following supplementation with sodium 
bicarbonate using a split-dose strategy. Pre-exercise blood bicarbonate concentrations 
compare favourably to those reported previously using different supplementation 
strategies but an identical dose 14, 19. However, only nine participants showed an 
improved exercise capacity with sodium bicarbonate ingestion above the CV of the 
test (4.94% 13). Blood data were also analysed according to the nine participants who 
showed an improved exercise capacity following sodium bicarbonate ingestion, and 
the twelve who did not. The change in blood bicarbonate, pH and base excess 
between baseline and pre-exercise following sodium bicarbonate ingestion were 
similar between individuals who improved and those who did not. This suggests that 
the underlying mechanism for an ergogenic effect of sodium bicarbonate 
supplementation was attained in all participants and thus was not an explanation for 
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the non-response. Further confirmation is provided by the fact that exercise capacity 
was not correlated to either the absolute concentration of, or the change in (from 
baseline to pre-exercise), any blood marker for all participants, suggesting that the 
degree of individual blood alkalosis prior to exercise did not influence the individual 
response in exercise capacity.  
 
Whilst there were no differences between individuals who improved and who did not 
in the ability of sodium bicarbonate ingestion to promote blood alkalosis, the 
reduction in blood pH, bicarbonate and base excess from pre- to post-exercise was 
significantly greater in the sodium bicarbonate trial for the group who improved but 
not for those who did not. This might suggest that promoting blood alkalosis 
concentration through sodium bicarbonate supplementation does not necessarily 
increase blood bicarbonate buffering in all individuals during high-intensity exercise. 
As such, a potential difference exists in the ability of individuals to make full use of 
the induced blood alkalosis, which might explain the individual exercise capacity 
responses to sodium bicarbonate. Surprisingly however, TWD was not correlated to 
any change in blood measurements for the group of individuals who improved their 
exercise capacity, but was correlated to the change from pre- to post-exercise in blood 
pH, bicarbonate and base excess for the group who did not improve. 
 
Ibanez et al. 20 reviewed the association between changes in peak blood lactate and 
exercise performance changes across 19 studies examining the potential ergogenic 
effects of alkalinising treatments. They suggested that a difference in blood lactate 
concentration of 2 mmol·L-1 between treatments was required to show a performance 
effect. In the present study, there was a difference between trials of +2.6 mmol·L-1 in 
peak blood lactate concentration immediately post-exercise in the group who 
improved, whereas there was an equivalent difference of only +0.7 mmol·L-1 in the 
group who did not improve their exercise capacity. As such, we provide some 
evidence to support the assertions of Ibanez et al. 20 since immediately post-exercise 
blood lactate concentrations were significantly higher in the sodium bicarbonate trial 
compared to the placebo trial for individuals who improved but not for those who did 
not. Furthermore, these results are consistent with a mechanism for the ergogenic 
effect of sodium bicarbonate being mediated by an increased efflux from muscle of 
lactate in association with H+, along with improved intracellular pH regulation during 
exercise, and that where this does not occur there is no improvement. However, these 
findings are in contrast to those of Price and Simons 9, who showed that individuals 
whose performance worsened with sodium bicarbonate had a greater blood lactate 
response to exercise. This study investigated the variability in response to sodium 
bicarbonate supplementation during a single trial using a cycling capacity test 
previously shown to be limited by increasing acidosis. Further investigation should 
incorporate multiple sodium bicarbonate trials at the same intensity to determine 
whether exercise and blood responses to sodium bicarbonate supplementation are 
consistent within individuals. 
 
Practical Applications 
Sodium bicarbonate supplementation did not significantly improve exercise capacity, 
although exercise capacity was improved when the data from participants reporting 
GI discomfort were removed from the analyses. Furthermore, since magnitude based 
inferences suggest that sodium bicarbonate is unlikely to be negative, individuals 
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should engage in supplementation during training in order to determine whether they 
can tolerate the supplement, and if they attain any exercise benefit. 
 
Conclusions 
Sodium bicarbonate supplementation did not significantly improve exercise capacity 
during a cycling test likely to be limited by increasing muscle acidosis, although 
magnitude based inferences suggest a 63% likelihood of a significant positive effect. 
Furthermore, exercise capacity was improved when the data from participants 
reporting GI discomfort were removed from the analyses, although GI discomfort 
could not explain a lack of an effect in all participants. Variability in exercise capacity 
and some blood responses between trials suggests that sodium bicarbonate 
supplementation may be beneficial to some, but not all individuals. 
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Figures 
 
 
 
Figure 1. Individual TWD (kJ) in the CCT110% in both P (black) and SB (white). 
Participants 18 – 21 are the participants who experienced gastrointestinal symptoms.  
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TABLE 1. TWD for all participants (N = 21), excluding those who experienced 
gastrointestinal discomfort (N = 17) and for participants who improved exercise 
capacity (Improved) and participants who did not improve exercise capacity (Non-
Improved). *P ≤ 0.01 from placebo trial. 
 
                       
  TWD (kJ) 
 
 
N = 21   
Placebo 45.6 ± 8.4  
NaHCO3
- 46.8 ± 9.1  
    
N = 17   
Placebo 46.2 ± 9.2  
NaHCO3
- 48.4 ± 9.3*  
   
Improved (N = 9)  
Placebo 43.1 ± 7.3  
NaHCO3
- 47.5 ± 8.1*  
   
Non-Improved (N = 12)  
Placebo 47.5 ± 9.0  
NaHCO3
- 46.2 ± 10.1  
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TABLE 2. pH, bicarbonate, base excess and lactate for all participants (N = 21) and 
excluding those who experienced gastrointestinal discomfort (N = 17). Data are mean 
± SD. (*P ≤ 0.01 from baseline; ^ P ≤ 0.01 from placebo trial at the same time point). 
 
  
 Baseline Pre-exercise Post-exercise Post-ex +5 
min 
N = 21     
pH     
Placebo 7.407±0.021 7.402±0.024 7.236±0.044* 7.229±0.056* 
NaHCO3
- 7.401±0.015 7.461±0.020*^ 7.292±0.054*^ 7.283±0.054*^ 
     
Bicarbonate (mmol·L-1)    
Placebo 24.79±1.14 24.96±0.99 14.43±1.89* 12.82±2.10* 
NaHCO3
- 24.66±1.44 30.40±1.01*^ 18.39±2.52*^ 15.26±2.78*^ 
     
Base excess (mmol·L-1)    
Placebo 0.78±0.98 0.82±0.78 -10.48±2.06* -12.69±2.80* 
NaHCO3
- 0.54±1.28 6.49±1.03*^ -6.89±3.11*^ -9.60±3.38*^ 
     
Lactate (mmol·L-1)    
Placebo 1.2±0.4 1.2±0.5 12.6±2.4* 12.4±2.0* 
NaHCO3
- 1.1±0.4 1.2±0.3 14.4±3.4*^ 14.5±2.9*^ 
     
     
N = 17     
pH     
Placebo 7.407±0.023 7.398±0.024 7.226±0.039* 7.215±0.048* 
NaHCO3
- 7.400±0.017 7.459±0.020*^ 7.276±0.036*^ 7.268±0.041*^ 
     
Bicarbonate 
(mmol·L-1) 
    
Placebo 24.79±1.24 24.87±1.07 15.16±1.78* 12.32±1.84* 
NaHCO3
- 24.51±1.41 30.33±1.08*^ 17.52±1.68*^ 14.41±2.07*^ 
     
Base excess 
(mmol·L-1) 
    
Placebo 0.70±1.08 0.66±0.75 -10.90±1.77* -13.40±2.40* 
NaHCO3
- 0.39±1.27 6.39±1.05*^ -7.94±1.98*^ -10.61±2.53*^ 
     
Lactate 
(mmol·L-1) 
    
Placebo 1.2±0.3 1.3±0.5 13.0±2.4* 12.9±1.4* 
NaHCO3
- 1.2±0.4 1.2±0.3 15.5±2.6*^ 15.5±1.8*^ 
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TABLE 3. Changes in pH, bicarbonate, base excess and lactate from baseline to pre-
exercise and pre-exercise to post-exercise for participants who improved exercise 
capacity (Improved) and participants who did not improve exercise capacity (Non- 
Improved) in SB. (*P ≤ 0.001 from placebo trial; ^P ≤ 0.01 from placebo trial). 
 
  
         Δ Baseline to Pre-Ex 
 
Δ Pre-Ex to Post-Ex 
 
 
pH 
Improved 
Placebo 
NaHCO3
- 
 
Non-Improved 
Placebo 
NaHCO3
- 
 
Bicarbonate (mmol.L-1) 
Improved 
Placebo 
NaHCO3
- 
 
Non-Improved 
Placebo 
NaHCO3
- 
 
Base Excess (mmol.L-1) 
Improved 
Placebo 
NaHCO3
- 
 
Non-Improved 
Placebo 
NaHCO3
- 
 
Lactate (mmol.L-1) 
Improved 
Placebo 
NaHCO3
- 
 
Non-Improved 
Placebo 
NaHCO3
- 
  
 
 
- 0.014 ± 0.036 
+ 0.060 ± 0.020* 
 
 
+ 0.002 ± 0.020 
+ 0.060 ± 0.015* 
 
 
 
+ 0.41 ± 0.83 
+ 5.94 ± 0.90* 
 
 
+ 0.00 ± 0.35 
+ 5.58 ± 1.53* 
 
 
 
+ 0.01 ± 0.70 
+ 6.10 ± 0.72* 
 
 
+ 0.08 ± 0.51 
+ 5.84 ± 1.35* 
 
 
 
  + 0.1 ± 0.5 
  + 0.1 ± 0.4 
 
 
               + 0.0 ± 0.5   
              + 0.1 ± 0.4 
  
 
 
- 0.158 ± 0.029 
- 0.184 ± 0.031^ 
 
 
- 0.173 ± 0.047 
- 0.158 ± 0.056 
 
 
 
- 9.19 ± 1.42 
- 12.79 ± 1.84* 
 
 
- 9.78 ± 2.10 
- 11.43 ± 2.46 
 
 
 
-10.89 ± 1.45 
- 14.36 ± 1.97* 
 
 
-11.60 ± 2.38 
- 12.65 ± 3.03 
 
 
 
+ 11.0 ± 2.4 
+ 14.0 ± 3.5* 
 
 
+ 11.8 ± 2.7 
+ 12.6 ± 3.5 
     
  
 
